ZYMEWORKS INC (ZYME) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:ZYME • US98985Y1082

22.51 USD
-0.21 (-0.92%)
At close: Feb 9, 2026
22.5 USD
-0.01 (-0.04%)
Pre-Market: 2/10/2026, 5:06:07 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

Taking everything into account, ZYME scores 4 out of 10 in our fundamental rating. ZYME was compared to 523 industry peers in the Biotechnology industry. While ZYME has a great health rating, there are worries on its profitability. ZYME shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • ZYME had negative earnings in the past year.
  • In the past year ZYME has reported a negative cash flow from operations.
  • ZYME had negative earnings in 4 of the past 5 years.
  • In the past 5 years ZYME reported 4 times negative operating cash flow.
ZYME Yearly Net Income VS EBIT VS OCF VS FCFZYME Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M -200M

1.2 Ratios

  • ZYME has a better Return On Assets (-15.97%) than 79.16% of its industry peers.
  • Looking at the Return On Equity, with a value of -19.82%, ZYME belongs to the top of the industry, outperforming 83.37% of the companies in the same industry.
Industry RankSector Rank
ROA -15.97%
ROE -19.82%
ROIC N/A
ROA(3y)-9.25%
ROA(5y)-23.15%
ROE(3y)-12.18%
ROE(5y)-33.12%
ROIC(3y)N/A
ROIC(5y)N/A
ZYME Yearly ROA, ROE, ROICZYME Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40 -60 -80

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for ZYME so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ZYME Yearly Profit, Operating, Gross MarginsZYME Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • ZYME does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, ZYME has less shares outstanding
  • Compared to 5 years ago, ZYME has more shares outstanding
  • ZYME has a better debt/assets ratio than last year.
ZYME Yearly Shares OutstandingZYME Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
ZYME Yearly Total Debt VS Total AssetsZYME Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

  • ZYME has an Altman-Z score of 10.47. This indicates that ZYME is financially healthy and has little risk of bankruptcy at the moment.
  • ZYME's Altman-Z score of 10.47 is amongst the best of the industry. ZYME outperforms 82.60% of its industry peers.
  • There is no outstanding debt for ZYME. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 10.47
ROIC/WACCN/A
WACC12.43%
ZYME Yearly LT Debt VS Equity VS FCFZYME Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

  • A Current Ratio of 6.94 indicates that ZYME has no problem at all paying its short term obligations.
  • With a decent Current ratio value of 6.94, ZYME is doing good in the industry, outperforming 70.17% of the companies in the same industry.
  • A Quick Ratio of 6.94 indicates that ZYME has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 6.94, ZYME is in the better half of the industry, outperforming 70.55% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.94
Quick Ratio 6.94
ZYME Yearly Current Assets VS Current LiabilitesZYME Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 34.37% over the past year.
  • ZYME shows a strong growth in Revenue. In the last year, the Revenue has grown by 116.21%.
  • Measured over the past years, ZYME shows a very strong growth in Revenue. The Revenue has been growing by 20.93% on average per year.
EPS 1Y (TTM)34.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
Revenue 1Y (TTM)116.21%
Revenue growth 3Y41.91%
Revenue growth 5Y20.93%
Sales Q2Q%72.59%

3.2 Future

  • The Earnings Per Share is expected to grow by 18.23% on average over the next years. This is quite good.
  • The Revenue is expected to grow by 30.49% on average over the next years. This is a very strong growth
EPS Next Y27.6%
EPS Next 2Y30.03%
EPS Next 3Y17.44%
EPS Next 5Y18.23%
Revenue Next Year34.71%
Revenue Next 2Y61.35%
Revenue Next 3Y26.99%
Revenue Next 5Y30.49%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ZYME Yearly Revenue VS EstimatesZYME Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M
ZYME Yearly EPS VS EstimatesZYME Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 -4

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • ZYME reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year ZYME is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ZYME Price Earnings VS Forward Price EarningsZYME Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ZYME Per share dataZYME EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3 4

4.3 Compensation for Growth

  • A more expensive valuation may be justified as ZYME's earnings are expected to grow with 17.44% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.03%
EPS Next 3Y17.44%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • ZYME does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ZYMEWORKS INC

NASDAQ:ZYME (2/9/2026, 8:00:03 PM)

Premarket: 22.5 -0.01 (-0.04%)

22.51

-0.21 (-0.92%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06
Earnings (Next)03-03
Inst Owners97.39%
Inst Owner Change-0.85%
Ins Owners0.7%
Ins Owner Change14.27%
Market Cap1.68B
Revenue(TTM)134.48M
Net Income(TTM)-63.43M
Analysts85
Price Target36.33 (61.39%)
Short Float %5.3%
Short Ratio4.15
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)63.29%
Min EPS beat(2)20.62%
Max EPS beat(2)105.95%
EPS beat(4)3
Avg EPS beat(4)-13.1%
Min EPS beat(4)-206.99%
Max EPS beat(4)105.95%
EPS beat(8)6
Avg EPS beat(8)-2.48%
EPS beat(12)8
Avg EPS beat(12)-2.95%
EPS beat(16)12
Avg EPS beat(16)3.95%
Revenue beat(2)1
Avg Revenue beat(2)69.22%
Min Revenue beat(2)-8.1%
Max Revenue beat(2)146.55%
Revenue beat(4)2
Avg Revenue beat(4)33.61%
Min Revenue beat(4)-32.69%
Max Revenue beat(4)146.55%
Revenue beat(8)4
Avg Revenue beat(8)11.83%
Revenue beat(12)7
Avg Revenue beat(12)16.19%
Revenue beat(16)8
Avg Revenue beat(16)13.31%
PT rev (1m)0.22%
PT rev (3m)43.9%
EPS NQ rev (1m)1.49%
EPS NQ rev (3m)-118.76%
EPS NY rev (1m)0.67%
EPS NY rev (3m)-18.37%
Revenue NQ rev (1m)-1.97%
Revenue NQ rev (3m)-70.16%
Revenue NY rev (1m)-0.29%
Revenue NY rev (3m)-18.25%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 12.53
P/FCF N/A
P/OCF N/A
P/B 5.26
P/tB 5.49
EV/EBITDA N/A
EPS(TTM)-0.84
EYN/A
EPS(NY)-0.43
Fwd EYN/A
FCF(TTM)-0.88
FCFYN/A
OCF(TTM)-0.86
OCFYN/A
SpS1.8
BVpS4.28
TBVpS4.1
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -15.97%
ROE -19.82%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-9.25%
ROA(5y)-23.15%
ROE(3y)-12.18%
ROE(5y)-33.12%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 24.88%
Cap/Sales 1.45%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.94
Quick Ratio 6.94
Altman-Z 10.47
F-Score6
WACC12.43%
ROIC/WACCN/A
Cap/Depr(3y)85.79%
Cap/Depr(5y)108.98%
Cap/Sales(3y)4.19%
Cap/Sales(5y)15.7%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)34.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
EPS Next Y27.6%
EPS Next 2Y30.03%
EPS Next 3Y17.44%
EPS Next 5Y18.23%
Revenue 1Y (TTM)116.21%
Revenue growth 3Y41.91%
Revenue growth 5Y20.93%
Sales Q2Q%72.59%
Revenue Next Year34.71%
Revenue Next 2Y61.35%
Revenue Next 3Y26.99%
Revenue Next 5Y30.49%
EBIT growth 1Y41.94%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year58.33%
EBIT Next 3Y35.99%
EBIT Next 5YN/A
FCF growth 1Y-134.5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-132.93%
OCF growth 3YN/A
OCF growth 5YN/A

ZYMEWORKS INC / ZYME FAQ

What is the ChartMill fundamental rating of ZYMEWORKS INC (ZYME) stock?

ChartMill assigns a fundamental rating of 4 / 10 to ZYME.


What is the valuation status of ZYMEWORKS INC (ZYME) stock?

ChartMill assigns a valuation rating of 0 / 10 to ZYMEWORKS INC (ZYME). This can be considered as Overvalued.


Can you provide the profitability details for ZYMEWORKS INC?

ZYMEWORKS INC (ZYME) has a profitability rating of 1 / 10.


How financially healthy is ZYMEWORKS INC?

The financial health rating of ZYMEWORKS INC (ZYME) is 8 / 10.


Can you provide the expected EPS growth for ZYME stock?

The Earnings per Share (EPS) of ZYMEWORKS INC (ZYME) is expected to grow by 27.6% in the next year.